Medication Status and Adherence of the Elderly under Home Care Nursing

Kim, Young Hee; Lee, Mi Kyoung; Lee, Sung Ja; Cho, Myung Sook; Hwang, Moon Sook

doi:10.12799/jkachn.2011.22.3.290

Cited by 12 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comorbidities are essential factors for predicting asthma control ( 9 20 ). The prevalence of comorbid conditions varies depending on study populations ( 17 18 19 21 ). One study revealed rhinitis is the most prevalent comorbid condition ( 19 ), while the others reported hypertension was the most prevalent one, in concordance with the present study ( 17 18 ).…”

Section: Discussionmentioning

confidence: 99%

Predictors of Asthma Control by Stepwise Treatment in Elderly Asthmatic Patients

Ban

Lee

et al. 2015

J Korean Med Sci

View full text Add to dashboard Cite

The geriatric population is increasing, and asthma severity increases with age. We determined the predictors of asthma control, exacerbation, and the factors that affect asthma-specific quality of life (A-QOL) in elderly asthmatic patients. This was a prospective, multicenter, real-life study for 6 months with stepwise pharmacologic treatment based on the Global Initiative for Asthma (GINA) guideline. A total of 296 asthmatic patients aged ≥ 60 yr were recruited from 5 university centers in Korea. The improved-asthma control group was defined as the group of patients who maintained well-controlled or improved disease and the not-improved asthma control group was defined as the remaining patients. Fewer number of medications for comorbidities (2.8 ± 3.3 in the improved vs. 4.5 ± 4.4 in the control) and higher physical functioning (PF) scale (89.8 ± 14.2 in the improved vs. 82.0 ± 16.4 in the control) were significant predictors in the improved-asthma control group (OR = 0.863, P = 0.004 and OR = 1.028, P = 0.018, respectively). An asthma control test (ACT) score of ≤ 19 at baseline was a significant predictor of asthma exacerbation (OR = 3.938, P = 0.048). Asthma duration (F = 5.656, P = 0.018), ACT score (F = 12.237, P = 0.001) at baseline, and the presence of asthma exacerbation (F = 5.565, P = 0.019) were significant determinants of changes in A-QOL. The number of medications for comorbidities and performance status determined by the PF scale may be important parameters for assessing asthma control in elderly asthmatic patients.Graphical Abstract

show abstract

Section: Discussionmentioning

confidence: 99%

Predictors of Asthma Control by Stepwise Treatment in Elderly Asthmatic Patients

Ban

Lee

et al. 2015

J Korean Med Sci

View full text Add to dashboard Cite

show abstract

“…This highlights the need to manage medical use and prescription for older female patients in Korea, as they have a longer life expectancy and higher medical utilization as compared to males. [25] Moreover, the reported increase in the number of prescribed drugs and daily dosing frequency among older patients in Korea can affect medication compliance, [26][27][28] further emphasizing the need for management of such prescriptions. In 2020, the number of records of PIMs for older patients decreased dramatically, and this could be attributed to the decrease in the use of health insurance in Korea due to the coronavirus disease (COVID-19) pandemic worldwide.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Analysis of the prescription trends of potentially inappropriate medications in Korean older outpatients by sex: A retrospective study using data from the health insurance review and assessment service

Dong,

Ju,

Yang

2023

Medicine

View full text Add to dashboard Cite

This study aimed to determine the policy implications for drug management by identifying the prescription trends of potentially inappropriate medications (PIMs) in older outpatients. Considering the Drug Utilization Review and Korean version of the standards for PIMs based on the Beers Criteria, 141 ingredients were selected that spanned over 7 years of health insurance claims data analysis. During the study period, the number of patients and claims related to PIMs increased. Although the number of health insurance claims decreased in 2020 owing to coronavirus disease (COVID-19), it increased again in 2021. Tamsulosin was the most frequently prescribed drug for male patients, followed by alprazolam and zolpidem. For female patients, eperisone was the most frequently prescribed drug, followed by alprazolam, zolpidem, and etizolam. In Korea, health insurance claims for PIMs decreased in 2020 owing to the COVID-19 pandemic. However, an overall increasing trend was observed from 2015 to 2021. Moreover, during this period, the prescription trend of benzodiazepine-type drugs and zolpidem increased in both male and female patients. Therefore, management policies regarding PIMs and drug ingredients, such as benzodiazepines and zolpidem, are required.

show abstract

“…A previously reported standard of adherence was 80% or higher;[ 26 ] thus, adherence measured by the participants' pill count values was high at 91.25% compared to a study on the adherence of elderly participants in home care (88.3%). [ 27 ] Age is an influential factor for adherence,[ 8 ] and the participants of this study with a mean age of 50.52 years were younger than those elderly participants. On the other hand, the adherence score measured by self-report (MMAS-8) had a mean of 5.89, indicating a low level of adherence, and was lower than the mean of 7.38 (intermediate adherence) for oral chemotherapy adherence demonstrated in colorectal cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Perceived New Normal and Inner Strength on Quality of Life in Breast Cancer Patients Receiving Adjuvant Endocrine Therapy

Ryu

2021

Asia-Pacific Journal of Oncology Nursing

View full text Add to dashboard Cite

Objective: This study aimed to investigate the differences in symptom experience, inner strength, adherence, and quality of life (QOL) according to the perception of the new normal, and identify the factors related to the QOL of breast cancer patients undergoing adjuvant hormonal therapy based on the theory of inner strength in women. Methods: This cross-sectional study recruited patients with breast cancer receiving adjuvant hormonal therapy in the National Cancer Center. Demographic and clinical characteristics were recorded, and patients were assessed using the M. D. Anderson Symptom Inventory, Connor-Davidson Resilience Scale 2, Morisky Medication Adherence Scale 8, and Functional Assessment of Cancer Therapy-General Scale. Results: After the breast cancer diagnosis, the perception of the new normal showed a significant dependence on pill count and emotional and functional well-being. The hierarchical regression analysis indicated that the new normal, symptom interference, and inner strength after adjusting for age, time since diagnosis, and receiving chemotherapy were significant predictors of QOL in breast cancer patients receiving adjuvant endocrine therapy. The model accounted for 47.8% of the variance in QOL. Conclusions: The theory of inner strength might be a potential pathway in health care to improve patients' QOL during long-term medication. The results of this study have both theoretical and applied implications. The findings can be utilized as evidence for developing an effective intervention that improves the QOL and adherence to adjuvant hormonal therapy of breast cancer patients.

show abstract

Medication Status and Adherence of the Elderly under Home Care Nursing

Cited by 12 publications

References 7 publications

Predictors of Asthma Control by Stepwise Treatment in Elderly Asthmatic Patients

Predictors of Asthma Control by Stepwise Treatment in Elderly Asthmatic Patients

Analysis of the prescription trends of potentially inappropriate medications in Korean older outpatients by sex: A retrospective study using data from the health insurance review and assessment service

Perceived New Normal and Inner Strength on Quality of Life in Breast Cancer Patients Receiving Adjuvant Endocrine Therapy

Contact Info

Product

Resources

About